503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines
Federal law gives compounders two routes, with different rules on prescriptions, quality standards, oversight and copies of approved drugs. Here is how they compare, using GLP-1 compounding as the worked example.
The signal
Federal law recognizes two compounding pathways: section 503A, for state-licensed pharmacies and physicians compounding for identified patients, and section 503B, for registered outsourcing facilities that must meet current good manufacturing practice requirements.
Why this matters
The pathway determines whether a patient-specific prescription is needed, which quality requirements apply, how FDA oversees the compounder and when copies of approved drugs may be made — the questions at the center of GLP-1 compounding as those medicines moved onto and off FDA’s drug shortage list.
NPHLA takeaway
The legal pathway, not the product name, decides the rules. Before relying on a compounded GLP-1 product, pharmacies, prescribers and clinics should confirm whether it was made under section 503A or 503B and check FDA’s current shortage status and statements. This is general information, not legal advice.
Source file
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
Drafted with AI assistance from the sources listed in the Source File, then reviewed and approved by an NPHLA editor before publication. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.